DOCSLIB.ORG

Supplementary Information Development and Application of A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Information Development and Application of A Electronic Supplementary Material (ESI) for Physical Chemistry Chemical Physics. This journal is © the Owner Societies 2019 Supplementary Information Development and Application of a Comprehensive Machine Learning Program for Predicting Molecular Biochemical and Pharmacological Properties Hwanho Choi, Hongsuk Kang, Kee-Choo Chung, and Hwangseo Park* Sejong Battery Institute, Sejong University, 209 Neungdong-ro, Kwangjin-gu, Seoul 05006, South Korea *Author to whom correspondence should may be addressed. [email protected] Chemical structures of the molecules in pKi (thrombin), logD, PCaco-2, S2-S16 and CLint datasets. Linear correlation diagrams between the experimental and calculated S17-S21 logD values of 53 SAMPL5 molecules in the 5-fold external cross- validation. Linear correlation diagrams between the experimental and calculated S22-S26 logCLint values of 37 drug molecules in the 5-fold external cross- validation. S1 Table S1. Chemical structures of 88 thrombin inhibitors. Indicated in red are the molecules in the training set. 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 S2 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 S3 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 S4 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 S5 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 S6 88 S7 Table S2. Chemical structures of 53 SAMPL5 molecules SAMPL5_002 SAMPL5_003 SAMPL5_004 SAMPL5_005 SAMPL5_006 SAMPL5_007 SAMPL5_010 SAMPL5_011 SAMPL5_013 SAMPL5_015 SAMPL5_017 SAMPL5_019 SAMPL5_020 SAMPL5_021 SAMPL5_024 SAMPL5_026 SAMPL5_027 SAMPL5_033 S8 SAMPL5_037 SAMPL5_042 SAMPL5_044 SAMPL5_045 SAMPL5_046 SAMPL5_047 SAMPL5_048 SAMPL5_049 SAMPL5_050 SAMPL5_055 SAMPL5_056 SAMPL5_058 SAMPL5_059 SAMPL5_060 SAMPL5_061 SAMPL5_063 SAMPL5_065 SAMPL5_067 S9 SAMPL5_068 SAMPL5_069 SAMPL5_070 SAMPL5_071 SAMPL5_072 SAMPL5_074 SAMPL5_075 SAMPL5_080 SAMPL5_081 SAMPL5_082 SAMPL5_083 SAMPL5_084 SAMPL5_085 SAMPL5_086 SAMPL5_088 SAMPL5_090 SAMPL5_092 S10 Table S3. Chemical structures of 38 drug molecules in Caco-2 dataset. Indicated in red are the molecules in the training set. Salicylic acid Dopamine Urea Phenytoin Acyclovir Alprenolol Atenolol Caffeine Chlorpromazine Clonidine Desipramine Diazepam Ganciclovir Indomethacin Labetalol S11 Metoprolol Pindolol Propranolol Terbutaline Timolol Dexamethasone Corticosterone Hydrocortisone Estradiol Sucrose Progesterone Aminophenazone Testosterone Mannitol Phencyclidine Zidovudine Nadolol Nicotine S12 Bremazocine Scopolamine Sulfasalazine Meloxicam Warfarin S13 Table S4. Chemical structures of 37 drug molecules in CLint dataset Phenytoin Metoprolol Amitryptyline Omeprazole Diltiazem Clozapine Alprazolam Zolpidem Imipramine Tenoxicam Methohexital Chlorpromazine Methoxsalen Propranolol Diclofenac Nicardipine Prednisone Verapamil S14 Midazolam Diazepam Triazolam Quinidine Ibuprofen Diphenhydramine Fluvastatin Tolbutamide Desipramine Propafenone Dexamethasone Amobarbital Hexobarbital Phenacetin Nilvadipine Lorcainide FK1052 FK480 S15 Tenidap S16 Figure S1. Linear correlation diagrams between the experimental and calculated results for logD values of the molecules in training (black) and test set (red). Fold #1 Compounds in the training set: 002, 003, 004, 006, 007, 010, 011, 015, 017, 019, 021, 024, 026, 027, 037, 042, 045, 046, 048, 049, 050, 055, 056, 058, 059, 060, 063, 065, 070, 072, 074, 075, 081, 082, 083, 084, 088, 090, 092 Compounds in the test set: 005, 013, 020, 033, 044, 047, 061, 067, 068, 069, 071, 080, 085, 086 S17 Figure S2. Linear correlation diagrams between the experimental and calculated results for LogD values of the molecules in training (black) and test set (red). Fold #2 Compounds in the training set: 003, 005, 006, 007, 010, 011, 015, 017, 019, 020, 024, 027, 033, 037, 042, 044, 045, 048, 049, 055, 058, 059, 060, 061, 065, 067, 068, 069, 072, 074, 075, 080, 082, 083, 084, 085, 088, 090, 092 Compounds in the test set: 002, 004, 013, 021, 026, 046, 047, 050, 056, 063, 070, 071, 081, 086 S18 Figure S3. Linear correlation diagrams between the experimental and calculated results for LogD values of the molecules in training (black) and test set (red). Fold #3 Compounds in the training set: 002, 003, 004, 005, 006, 007, 010, 011, 013, 015, 017, 020, 021, 024, 026, 027, 033, 037, 044, 046, 047, 048, 049, 050, 055, 058, 059, 063, 065, 069, 071, 080, 081, 082, 083, 084, 085, 088, 090 Compounds in the test set: 019, 042, 045, 056, 060, 061, 067, 068, 070, 072, 074, 075, 086, 092 S19 Figure S4. Linear correlation diagrams between the experimental and calculated results for LogD values of the molecules in training (black) and test set (red). Fold #4 Compounds in the training set: 002, 003, 006, 007, 010, 011, 013, 015, 017, 019, 021, 026, 027, 033, 037, 042, 044, 045, 046, 047, 055, 056, 058, 059, 060, 061, 063, 068, 070, 071, 072, 074, 080, 082, 083, 085, 086, 088, 090 Compounds in the test set: 004, 005, 020, 024, 048, 049, 050, 065, 067, 069, 075, 081, 084, 092 S20 Figure S5. Linear correlation diagrams between the experimental and calculated results for LogD values of the molecules in training (black) and test set (red). Fold #5 Compounds in the training set: 002, 003, 005, 006, 007, 010, 013, 015, 017, 019, 020, 024, 026, 027, 033, 037, 042, 044, 045, 048, 049, 056, 059, 061, 063, 065, 068, 069, 070, 071, 074, 075, 080, 082, 083, 084, 085, 090, 092 Compounds in the test set: 004, 011, 021, 046, 047, 050, 055, 058, 060, 067, 072, 081, 086, 088, S21 Figure S6. Linear correlation diagrams between the experimental and calculated results for logCL values of the molecules in training (black) and test set (red). Fold #1 Compounds in the training set: phenytoin, amitryptyline, omeprazole, clozapine, zolpidem, tenoxicam, methohexital, chlorpromazine, methoxsalen, propranolol, diclofenac, nicardipine, prednisone, verapamil, midazolam, diazepam, triazolam, quinidine, ibuprofen, diphenhydramine, fluvastatin, tolbutamide, desipramine, amobarbital, phenacetin, fk1052, lorcainide, tenidap Compounds in the test set: metoprolol, diltiazem, alprazolam, imipramine, propafenone, dexamethasone, hexobarbital, nilvadipine, fk480 S22 Figure S7. Linear correlation diagrams between the experimental and calculated results for logCL values of the molecules in training (black) and test set (red). Fold #2 Compounds in the training set: metoprolol, omeprazole, diltiazem, clozapine, alprazolam, imipramine, tenoxicam, methohexital, methoxsalen, propranolol, diclofenac, nicardipine, verapamil, midazolam, diazepam, triazolam, quinidine, ibuprofen, fluvastatin, desipramine, propafenone, dexamethasone, amobarbital, hexobarbital, phenacetin, nilvadipine, fk480, lorcainide Compounds in the test set: phenytoin, amitryptyline, zolpidem, chlorpromazine, prednisone, diphenhydramine, tolbutamide, fk1052, tenidap S23 Figure S8. Linear correlation diagrams between the experimental and calculated results for logCL values of the molecules in training (black) and test set (red). Fold #3 Compounds in the training set: phenytoin, amitryptyline, omeprazole, diltiazem, alprazolam, zolpidem, imipramine, tenoxicam, methoxsalen, propranolol, nicardipine, prednisone, verapamil, midazolam, diazepam, triazolam, quinidine, ibuprofen, diphenhydramine, fluvastatin, tolbutamide, desipramine, propafenone, amobarbital, phenacetin, nilvadipine, fk1052, fk480 Compounds in the test set: metoprolol, clozapine, methohexital, chlorpromazine, diclofenac, dexamethasone, hexobarbital, lorcainide, tenidap S24 Figure S9. Linear correlation diagrams between the experimental and calculated results for logCL values of the molecules in training (black) and test set (red). Fold #4 Compounds in the training set: metoprolol, amitryptyline, omeprazole, clozapine, alprazolam, zolpidem, tenoxicam, methohexital, chlorpromazine, methoxsalen, propranolol, diclofenac, nicardipine, prednisone, verapamil, diazepam, triazolam, quinidine, ibuprofen, fluvastatin, desipramine, propafenone, dexamethasone, amobarbital, phenacetin, nilvadipine, fk1052, tenidap Compounds in the test set: phenytoin, diltiazem, imipramine, midazolam, diphenhydramine, tolbutamide, hexobarbital, fk480, lorcainide S25 Figure S10. Linear correlation diagrams between the experimental and calculated results for logCL values of the molecules in training (black) and test set (red). Fold #5 Compounds in the training set: phenytoin, metoprolol, amitryptyline, omeprazole, diltiazem, zolpidem, imipramine, tenoxicam, methohexital, chlorpromazine, methoxsalen, diclofenac, prednisone, midazolam, triazolam, quinidine, diphenhydramine, fluvastatin, tolbutamide, desipramine, dexamethasone, amobarbital, hexobarbital, nilvadipine, fk1052, fk480, lorcainide, tenidap Compounds in the test set: clozapine, alprazolam, propranolol, nicardipine, verapamil, diazepam, ibuprofen, propafenone, phenacetin S26.
Load more

Recommended publications
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Determination of Barbiturates and 11-Nor-9-Carboxy-Δ9-THC in Urine
    Determination of Barbiturates and 11-Nor-9-carboxy- 9-THC in Urine using Automated Disposable Pipette Extraction (DPX) and LC/MS/MS Fred D. Foster, Oscar G. Cabrices, John R. Stuff, Edward A. Pfannkoch GERSTEL, Inc., 701 Digital Dr. Suite J, Linthicum, MD 21090, USA William E. Brewer Department of Chemistry and Biochemistry, University of South Carolina, 631 Sumter St. Columbia, SC 29208, USA KEYWORDS DPX, LC/MS/MS, Sample Preparation, High Throughput Lab Automation ABSTRACT This work demonstrates the use of disposable pipette extraction (DPX) as a fast and automated sample preparation technique for the determination of barbiturates and 11-nor-9- carboxy- 9-THC (COOH-THC) in urine. Using a GERSTEL MultiPurpose Sampler (MPS) with DPX option coupled to an Agilent 6460 LC-MS/MS instrument, 8 barbiturates and COOH-THC were extracted and their concentrations determined. The resulting average cycle time of 7 min/ sample, including just-in-time sample preparation, enabled high throughput screening. Validation results show that the automated DPX-LC/ AppNote 1/2013 MS/MS screening method provides adequate sensitivity for all analytes and corresponding internal standards that were monitored. Lower limits of quantitation (LLOQ) were found to be 100 ng/mL for the barbiturates and 10 ng/mL for COOH-THC and % CVs were below 10 % in most cases. INTRODUCTION The continuously growing quantity of pain management sample extract for injection [1-2]. The extraction of the drugs used has increased the demand from toxicology Barbiturates and COOH-THC is based on the DPX-RP- laboratories for more reliable solutions to monitor S extraction method described in an earlier Application compliance in connection with substance abuse and/or Note detailing monitoring of 49 Pain Management diversion.
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • International Classification of Diseases
    INTERNATIONAL CLASSIFICATION OF DISEASES MANUAL OF THE INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES, INJURIES, AND CAUSES OF DEATH Based on the Recommendations of the Eighth Revision Conference, 1965, and Adopted by the Nineteenth World Health Assembly Volume 2 ALPHABETICAL INDEX WORLD HEALTH ORGANIZATION GENEVA 1969 Volume 1 Introduction List of Three-digit Categories Tabular List of Inclusions and Four-digit Sub- categories Medical Certification and Rules for Classification Special Lists for Tabulation Definitions and Recommendations Regulations Volume 2 Alphabetical Index PRINTED IN ENGLAND CONTENTS Introduction Page General arrangement of the Index ....................................... VIII Main sections ............................................................... VIII Structure ..................................................................... IX Code numbzrs .............................................................. x Primary and secondary conditions. ................................... x Multiple diagnoses. ........................................................ XI Spelling....................................................................... XI Order of listing ............................................................. Conventions used in the Index ........................................... XII Parentheses. ................................................................. XII Cross-referexes ........................................................... XI1 Abbreviation NEC. ......................................................
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • A Fast Analytical LC/MS/MS Method for the Simultaneous Analysis of Barbiturates and 11-Nor-9-Carboxy-Δ9- Tetrahydrocannabinol (THC-A) in Urine
    Application Note Clinical Research A Fast Analytical LC/MS/MS Method for the Simultaneous Analysis of Barbiturates and 11-nor-9-carboxy-Δ9- tetrahydrocannabinol (THC-A) in Urine Using ESI negative ionization mode and alternating column regeneration Authors Abstract Andre Szczesniewski and Most of the compounds in large drug panels are analyzed using positive ionization Carrie J. Adler mode. However, barbiturates and 11-nor-9-carboxy-Δ9-THC (THC-A) perform better Agilent Technologies, Inc. using electrospray ionization (ESI) in negative mode with the mobile phase pH favorable for negative ionization. This work developed a fast analytical method combining eight barbiturates and THC-A in a single analysis using alternating column regeneration (ACR) to increase sample throughput. Moving the analytes preferring negative ionization into a separate test increases the analytical sensitivity of the compounds, allowing for greater research capabilities. The simple sample preparation techniques used provided rapid analysis, good analytical sensitivity, and quantitation over a wide dynamic range. This analysis used an Agilent 6470 triple quadrupole mass spectrometer with Agilent Jet Stream technology in ESI negative ionization mode and an Agilent Infinity II 1290 UHPLC system. A second pump and 2-position 10-port switching valve were added to facilitate use of the ACR. A 100 µL aliquot of human urine was used for the analysis of barbiturates and THC-A. Chromatographic separation of the analytes was achieved in less than 3 minutes using a gradient method composed of a H2O:acetonitrile mixture with 5 mM ammonium acetate and two Agilent Poroshell 120 EC-C18, 2.1 × 100 mm, 1.9 μm columns.
    [Show full text]
  • Brevital Sodium Methohexital Sodium for Injection
    BREVITAL® SODIUM METHOHEXITAL SODIUM FOR INJECTION, USP For Intravenous Use in Adults For Rectal and Intramuscular Use Only in Pediatric Patients WARNING Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient. (See WARNINGS) DESCRIPTION Brevital® Sodium (Methohexital Sodium for Injection, USP) is 2,4,6 (1H, 3H, 5H)- Pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (±)-, monosodium salt and has the empirical formula C14H17N2NaO3. Its molecular weight is 284.29. The structural formula is as follows: Methohexital sodium is a rapid, ultrashort-acting barbiturate anesthetic. Methohexital sodium for injection is a freeze-dried, sterile, nonpyrogenic mixture of methohexital sodium with 6% anhydrous sodium carbonate added as a buffer. It contains not less than 90% and not more than 110% of the labeled amount of methohexital sodium. It occurs as a white, freeze-dried plug that is freely soluble in water. This product is oxygen sensitive. The pH of the 1% solution is between 10 and 11; the pH of the 0.2% solution in 5% dextrose is between 9.5 and 10.5. Methohexital sodium may be administered by direct intravenous injection or continuous intravenous drip, intramuscular or rectal routes (see PRECAUTIONS—Pediatric Use).
    [Show full text]